From Wikipedia, the free encyclopedia
|Traded as||NASDAQ: PSDV ASX: PVA FWB: PV3|
|Headquarters||Watertown, Massachusetts, USA|
Number of locations
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ). QinetiQ continues to be a strategic partner.
- Alimera Sciences, pSvida's partner on Iluvien
- Official website
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
- Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015.
pSivida's Dinesh K. Nadarassan presented a poster entitled “Sustained Release of Bevacizumab (Avastin) from BioSilicon”
|This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it.|
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|